1. Heated Intraperitoneal Chemotherapy in the Management of Advanced Ovarian Cancer
- Author
-
Megan McMahon, Andrea Jewell, and Dineo Khabele
- Subjects
0301 basic medicine ,Oncology ,Hyperthermia ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Tumor penetration ,Review ,intraperitoneal chemotherapy (IP) ,lcsh:RC254-282 ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,cytoreductive surgery ,heated intraperitoneal chemotherapy (HIPEC) ,Chemotherapy ,Advanced ovarian cancer ,business.industry ,interval cytoreduction ,Intraperitoneal chemotherapy ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,secondary cytoreduction ,Regimen ,030104 developmental biology ,ovarian cancer ,030220 oncology & carcinogenesis ,Ovarian cancer ,business ,Blood stream - Abstract
Heated intraperitoneal chemotherapy (HIPEC) has several potential benefits. Higher doses of chemotherapy can be used with HIPEC because the plasma-peritoneal barrier results in little absorption into the blood stream. HIPEC offers higher peritoneal penetration in comparison to an intravenous (IV) regimen and does not have the traditional normothermic intraperitoneal (IP) regimen limitation of post-operative adhesions. Hyperthermia itself has cytotoxic effects and can potentiate antineoplastic effects of chemotherapy in part by increasing the depth of tumor penetration by up to 3 mm. For the treatment of ovarian cancer, HIPEC has been evaluated in the recurrent setting with secondary cytoreduction. Recent studies, including a prospective trial, have evaluated its role in primary management of ovarian cancer. This review summarizes previous and ongoing studies regarding the use of HIPEC in the management of ovarian cancer.
- Published
- 2018